-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With tyrosine kinase inhibitors, clinical outcomes improved in patients with acute lymphoblastic leukemia (ALL) who were positive for the Philadelphia chromosome (Ph), with molecular remission being the primary goal of treatment.
researchers recently examined the effects of dassartin, glucoticoids and bonatumant on molecular response in Ph-positive ALL patients.
this study was conducted in a single group of Phase II studies involving newly diagnosed PH-positive ALL patients who received 2 rounds of Bonathosis monotherapy after the completion of the glucosal hormone induction therapy.
end point of this study is the continuous molecular response of the bone marrow after treatment.
63 patients, with a middle age of 54 and 98 percent in complete remission.
At the end of the dasatinib-glucoticoid induction treatment (day 85), 29% of patients had a molecular response, which increased to 60% after two cycles of Bonathosis monotherapy, and the percentage of patients who received a molecular response increased further after the continuation of Bonathatone anti-maintenance therapy.
In the 18-month median follow-up, the total survival rate was 95% and the disease-free survival rate was 88%, but the disease-free survival rate was lower in patients with IKZF1 deficiency plus additional genetic distortions (CDKN2A, CDKN2B, PAX5 or both).
ABL1 mutation can be detected in 6 patients with increased residuals of minor diseases during induction therapy, but can be removed by Bonathosis.
cases have been reported in the past few years.
recorded a total of 21 adverse events of level 3 or higher.
24 patients received allogeneic stem cell transplants, and one death was related to transplantation (4%).
study concluded that for Philadelphia chromosomal-positive acute lymphoblastic leukemia, dassatinib, glucosal hormone combined with Bonatoda monoantimmune therapy can induce patients to have a sustained molecular response, to obtain a higher survival rate.
.
